Avalon BioVentures SPV I, L.P. is 10% Owner at Janux Therapeutics, Inc. (JANX). They have made 1 open-market trade across 1 company since 2024, most recently 2024-10-18.
CIK 0001844550
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| JANX | 6,371 | $105K |
Shares reported on the most recent Form 4, priced at the 2024-10-18 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| JANX | SELL | 2024-10-16 | 2024-10-18 | $46.58 | $129.7M | +11.9% | -3.8% | -18.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.